Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease

Frank Jessen, Javier Arbizu, Mercé Boada, Mircea Balasa, Karim Bennys, Marina Boban, Katharina Bürger, Andrea Chincarini, Annachiara Cagnin, Peter Paul De Deyn, Emrah Düzel, Sebastiaan Engelborghs, Michael Ewers, Lieza G Exalto, Wiesje M van der Flier, Juan Fortea, Kristian Steen Frederiksen, Giovanni B Frisoni, Lutz Frölich, Alejandro J Garza-Martinez, Timo Grimmer, Bernard Hanseeuw, Jakub Hort, Adrian Ivanoiu, Patrick G Kehoe, Sean P Kennelly, Silke Kern, Stefan Klöppel, Lenka Krajčovičová, Milica G Kramberger, Bernadette McGuinness, Patrizia Mecocci, Timo Jan Oberstein, Pierre-Jean Ousset, Claire Paquet, Robert Perneczky, Fabrizio Piazza, Domenico Plantone, Innocenzo Rainero, Guillaume Sacco, Eric Salmon, Isabel Santana, Nikolaos Scarmeas, Anja Schneider, Jonathan M Schott, Eino Solje, Elka Stefanova, Elisabeth Stögmann, Mélanie Strauss, Stanislav Sutovsky, Gunhild Waldemar, Bengt Winblad